The British Journal of Clinical Pharmacology

Volume 50
2000

Published for
The British Pharmacological Society by
Blackwell Science

© 2000 Blackwell Science Ltd
Osney Mead, Oxford OX2 0EL
25 John Street, London WC1N 2BL
23 Ainslie Place, Edinburgh EH3 6AJ
Commerce Place, 350 Main Street, Malden MA 02148-5018, USA
54 University Street, Carlton, Victoria 3053, Australia

Other Editorial Offices:
Blackwell Wissenschafts-Verlag GmbH
Kurfürstendamm 57
1707 Berlin
Germany

Blackwell Science KK
MG Kodenmacho Building
7–10 Kodenmacho Nihombashi
Chuo-ku, Tokyo 104
Japan

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Science for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $14.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01923, USA. 0206-5251/99 $14.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset, Printed and Bound by The Charlesworth Group, Huddersfield

Contents

This article is considered particularly suitable for continuing medical education.

Volume 50, Number 1, July 2000

Reviews

1 The impact of molecular medicine upon early cardiovascular drug development: *M.W. Lunnon & M. Braddock*

9 The acute vascular effect of frusemide in heart failure: *P.S. Jhund, J.J.V. McMurray & A.P. Davie*

15 Towards a blood test for heart failure: the potential use of circulating natriuretic peptides: *S. Talwar, P.F. Downie, L.L. Ng & I.B. Squire*

Pharmacodynamics

21 Diurnal variation in the quantitative EEG in healthy adult volunteers: *L. Cummings, A. Dane, J. Rhodes, P. Lynch & A.M. Hughes*

27 Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin S6c, in human resistance and capacitance vessels *in vivo*: *F.E. Strachan, T.R. Crockett, N.L. Mills, G.A. Gray & D. J. Webb*

Pharmacokinetics

31 Frequencies of *CYP2D6* mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different *CYP2D6* genotypes: *T. Kubota, Y. Yamaura, N. Ohkawa, H. Hara & K. Chiba*

Pharmacovigilance

35 The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19 087 patients in general practice in England: cohort study: *R.M. Martin, P. Biswas & R.D. Mann*

43 Intracranial haemorrhage and use of selective serotonin reuptake inhibitors: *F.J. de Abajo, H. Jick, L. Derby, S. Jick & S. Schmitz*

Drug utilization

48 Feasibility study of multicentre comparison of NHS hospital pharmacy computer data: *P.D. Walker & T. Walley*

Short reports

55 Nonprescription medicine use in a multiple sclerosis clinic population: *H.L. Tremlett, C.M. Wiles & D.K. Luscombe*

61 Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT_3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man: *K. Reid, J.L. Palmer, R.J. Wright, S.A. Clemes, C. Troakes, H.S. Somal, F. House & J.R.R. Stott*

65 Comparison of the effects of clonidine and yohimbine on pupillary diameter at different illumination levels: *M.A. Phillips, E. Szabadi & C.M. Bradshaw*

69 Absorption of lefradafiban from different sites of the gastrointestinal tract: *J. Drewe, H. Narjes, G. Heinzel, R.-S. Brickl, A. Rohr & C. Beglinger*

73 Ovarian hormones in man: their effects on resting vascular tone, angiotensin converting enzyme activity and angiotensin II-induced vasoconstriction: *A.F.C. Lee, L.C. McFarlane & A.D. Struthers*

77 CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system: *G.A. Ford, S.M. Wood & A.K. Daly*

Letters to the Editors

81 Angioedema and cough in Nigerian patients receiving ACE inhibitors: *A.A.L. Ajayi & A.Q. Adigun*

82 A drug interaction between fusidic acid and a combination of ritonavir and saquinavir: *Y. Khaliq, K. Gallicano, R. Leger, B. Foster & A. Badley*

Volume 50, Number 2, August 2000

Commentary

85 Commentary: *D.J. Back*

Reviews

87 Therapeutic potential of ischaemic preconditioning: *R.J. Edwards, A.T. Saurin, R.D. Rakhit & M.S. Marber*

Drug interaction

99 Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir: *G.J. Muirhead, M.B. Wulff, A. Fielding, D Kleinermans & N. Buss*

Pharmacodynamics

108 Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease: *Y. Khaliq, K. Gallicano, I. Seguin, K. Fyke, G. Carignan, D. Bulman, A. Badley & D.W. Cameron*

116 Pharmacokinetics of epimeric budenoside and fluticasone propionate after repeat dose inhilation – intersubject variability in systemic absorption from the lung: *C. Minto, B. Li, B. Tattam, K. Brown, J.P. Seale & R. Donnelly*

Population pharmacokinetics

125 A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children: *B.J. Anderson, G.A. Woollard & N.H.G. Holford*

135 Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children: *C. Chen*

Pharmacokinetics

146 Plasma erythropoietin levels in patients receiving intensive platinum or nonplatinum chemotherapy: *R. Canaparo, F. Casale, E. Muntoni, G.P. Zara, C. Della Pepa, E. Berno, N. Pons, G. Fornari & M. Eandi*

154 Effects of potassium channel opener KRN4884 on human conduit arteries used as coronary bypass grafts: *Z. Ren, M. Liu, A. Furnary, S. Floten, H. Gately, J. Swanson, A. Ahmad & G.-W. He*

Pharmacovigilance

161 First trimester exposure to cefuroxime: a prospective cohort study: *M. Berkovitch, I. Segal-Socher, R. Greenberg, M. Bulkowshtein, J. Arnon, P. Merlob & A. Or-Noy*

Drug compliance

166 Compliance with tricyclic antidepressants: the value of four different methods of assessment: *C.F. George, R.C. Peveler, S. Heiliger & C. Thompson*

172 Effects of a medicine review and education programme for older people in general practice: *C.J. Lowe, D.K. Raynor, J. Purvis, A.J. Farrin & J. Hudson*

Short reports

177 Pharmacokinetics and tolerability of intravenous infusion of adenosine (SUN Y4001) in healthy volunteers: *T. Uematsu, O. Kozawa, H. Matsuno, M. Niwa, H. Yoshikoshi, M. Oh-uchi, K. Kohno, S. Nagashima & M. Kanamaru*

Erratum

183 Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion *vs* intermittent bolus injection in septicaemic melioidosis: *B.J. Angus, M.D. Smith, Y. Suputtamongkol, H. Mattie, A.L. Walsh, V. Wuthiekanun, W. Chaowagul & N.J. White*

Volume 50, Number 3, September 2000

Pharmacokinetics

193 The effects of lamotrigine on the pharmacokinetics of lithium: *C. Chen, L. Veronese & Y. Yin*

197 Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam: *D. Türck, G. Heinzel & G. Luik*

Pharmacodynamics

205 Muscular and cardiorespiratory effects of pseudoephedrine in human athletes: *N.D. Gill, A. Shield, A. J. Blazevich, S. Zhou & R.P. Weatherby*

215 A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension: *P. Chan, B. Tomlinson, Y.-J. Chen, J.-C. Liu, M.-H. Hsieh & J.-T. Cheng*

221 Heparin-mediated selective release of hepatocyte growth factor in humans: *P. B. Salbach, M. Brückmann, O. Turovets, J. Kreuzer, W. Kübler & I. Walter-Sack*

227 Influence of asimadoline, a new κ-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man: *H.J. Kramer, W. Uhl, B. Ladstetter & A. Bäcker*

Pharmacokinetics/pharmacodynamics

237 Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine: *J. Drewe, H.A. Ball, C. Beglinger, B. Peng, A. Kemmler, H. Schächinger & W. E. Haefeli*

247 The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing: *M.J. Allen, D.J. Nichols & S.D. Oliver*

255 Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification *in vitro*: *R. Menéndez, R. Más, A. M. Amor, R. M. González, J. C. Fernández, I. Rodeiro, M. Zayas & S. Jiménez*

Drug disposition

263 Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants: *J. Rampono, J.H. Kristensen, L.P. Hackett, M. Paech, R. Kohan & K.F. Ilett*

Pharmacogenetics

269 Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations: *J.M. Morsman, J. Sludden, M.-M. Ameyaw, J. Githang'a, A. Indalo, D. Ofori-Adjei & H.L. McLeod*

Short reports

273 Intravenous diltiazem and CYP3A-mediated metabolism: *A.L. Masica, N.E. Azie, D.C. Brater, S.D. Hall & D.R. Jones*

277 Reducing electrostatic charge on spacer devices and bronchodilator response: *J.H. Wildhaber, G.W. Waterer, G.L. Hall & Q.A. Summers*

281 Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged: *V.L. Silkstone, H.S. Tomlinson, S.A. Corlett & H. Chrystyn*

Volume 50, Number 4, October 2000

Reviews

285 Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin: *J.F. Westphal*

297 Drug-induced proarrhythmic effects: assessment of changes in QT interval: *D.J. Sheridan*

Drug disposition

303 Parkinson's disease and CYP1A2 activity: *J.T. Forsyth, R.A. Grünewald, A. Rostami-Hodjegan, M.S. Lennard, H.J. Sagar & G.T. Tucker*

311 *In vitro* evaluation of potential *in vivo* probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms: *D.H. Lang & A.E. Rettie*

Population pharmacokinetics

315 Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study: *G. Freyer, B. Tranchand, B. Ligneau, C. Ardiet, P.J. Souquet, I. Court-Fortune, R. Riou, P. Rebattu, J.P. Boissel, V. Trillet-Lenoir & P. Girard*

Drug interaction

325 Effect of altered gastric emptying and gastrointestinal motility on metformin absorption: *P.H. Marathe, Y. Wen, J. Norton, D.S. Greene, R.H. Barbhaiya & I.R. Wilding*

333 Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation: *S. Palovaara, K.T. Kivistö, P. Tapanainen, P. Manninen, J.P. Neuvonen & K. Laine*

Pharmacokinetics/pharmacodynamics

338 A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers: *M. Bani, A. Colantoni, M. Guillaume, F. Macchi, G. Moroni & S. Persiani*

350 Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study: *P. Morain, J.L. Robin, G. De Nanteuil, R. Jochemsen, V. Heidet & D. Guez*

Pharmacodynamics

360 Effects of high ambient temperature on parasympathetically mediated cardiovascular reflexes in normal man: *W.M.A. Banjar, J. Gazzaz, R.W. Langley, C.M. Bradshaw & E. Szabadi*

Pharmacovigilance

366 The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies: *R.M. Martin, N.R. Dunn, S. Freemantle & S. Shakir*

Short reports

373 The pharmacokinetics of trinitroglycerin and its metabolites in patients with chronic stable angina: *S. Hashimoto, E. Yamauchi, A. Kobayashi, K. Shigemi, H. Tsuruta, T. Yamashita & Y. Tanaka*

377 Nebivolol decreases systemic oxidative stress in healthy volunteers: *R. Troost, E. Schwedhelm, S. Rojczyk, D. Tsikas & J.C. Frölich*

Letter to the Editors

381 Influences on plasma cortisol of different formulations of beclomethasone dipropionate: *B.J. Lipworth & C.M. Jackson*

Book review

382 Hands-on Guide to Clinical Pharmacology: *M. Walters*

383 **Proceedings of the British Pharmacological Society, Clinical Pharmacology Section, 12–14 July 2000, Cardiff University**

Volume 50, Number 5, November 2000

Editorials

393 Clinical pharmacology methodology: introduction: *N.S. Baber*

395 Research methods in human cardiovascular pharmacology: *S.R.J. Maxwell & D. Webb*

Reviews

397 *Research Methods in Human Cardiovascular Pharmacology*
edited by Dr S. Maxwell and Prof. D. Webb
Flow-mediated dilatation: *O.T. Raitakari & D.S. Celermajer*

405 *Therapeutics*
Drugs used in secondary prevention after myocardial infarction: Case presentation
S.R.J. Maxwell & W.S. Waring

419 Design issues for drug epidemiology: *A.D. McMahon & T.M. MacDonald*

Pharmacokinetics

427 Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients: *D.J.R. Foster, A.A. Somogyi, K.R. Dyer, J.M. White & F. Bochner*

Pharmacokinetics/pharmacodynamics

441 Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption: *S. Pace, A. Longo, S. Toon, P. Rolan & A.M. Evans*

449 Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD: *G.I. Kirchner, M. Winkler, L. Mueller, C. Vidal, W. Jacobsen, A. Franzke, S. Wagner, S. Blick, M.P. Manns & K.-F. Sewing*

455 Lack of effect of grapefruit juice on the parmacokinetics and pharmacodynamics of amlodipine: *J. Vincent, S.I. Harris, G. Foulds, L.C. Dogolo, S. Willavize & H.L. Friedman*

Drug disposition

465 Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol: *S.J. Porter, A.A. Somogyi & J.M. White*

Pharmacoepidemiology

473 Drug use of children in the community assessed through pharmacy dispensing data: *E. Schirm, P. van den Berg, H. Gebben, P. Sauer & L. de Jong-van den Berg*

Short report

479 Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals: *H. Bagheri, F. Michel, M. Lapeyre-Mestre, E. Lagier, J.P. Cambus, P. Valdiguié & J.L. Montastruc*

Proceedings

485 Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy:

Volume 50, Number 6, December 2000

Reviews

501 *Research Methods in Human Cardiovascular Pharmacology edited by Dr S. Maxwell and Prof. D. Webb*

Capillaroscopy and the measurement of capillary pressure: *A.C. Shore*

515 Quality use of medicines in the community: the Australian experience: *A.J. Smith & P. McGettigan*

521 Immunotherapy for renal carcinoma: theoretical basis and current standard of care: *P.A. Vasey*

Population pharmacokinetics

531 Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients: *W.J. Sam, M. Aw, S.H. Quak, S.M. Lim, B.G. Charles, S.Y. Chan & P.C. Ho*

543 Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects: *H. Zhou, T.L. Chen, M. Marino, H. Lau, T. Miller, G. Kalafsky & J.F. McLeod*

Pharmacogenetics

553 Benzydamine *N*-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of *FMO3* polymorphisms on enzyme activity: *E. Störmer, I. Roots & J. Brockmöller*

563 Identification of the human cytochrome P450 isoforms mediating the *in vitro* *N*-dealkylation of perphenazine: *O.V. Olesen & K. Linnet*

Drug disposition

573 The xenobiotic inhibitor profile of cytochrome P4502C8: *C.-E. Ong, S. Coulter, D.J. Birkett, C.R. Bhasker & J.O. Miners*

Drug interactions

581 Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine: *T. Kosoglou, M. Salfi, J.M. Lim, V.K. Batra, M.N. Cayen & M.B. Affrime*

591 Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride: *M. Niemi, K.T. Kivistö, J.T. Backman & P.J. Neuvonen*

597 The intracellular activation of lamivudine (3TC) and determination of 2′-deoxycytidine-5′-triphosphate (DCTP) pools in the presence and absence of various drugs in HepG2 cells: *S. Kewn, P.G. Hoggard, S.D. Sales, M.A. Johnson & D.J. Back*

Pharmacokinetics/pharmacodynamics

605 Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis: *P.R. Mayo, K. Skeith, A.S. Russell & F. Jamali*

Pharmacodynamics

615 Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension: *J. Minami, Y. Kawano, Y. Makino, H. Matsuoka & S. Takishita*

Short Report

621 The influence of the hand circulation on the assessment of venous distensibility of the human forearm with venous occlusion plethysmography: *J. Burggraaf, M.J.B. Kemme, L.M. Muller, R.C. Schoemaker & A.F. Cohen*

Book review

624 Medical Statistics – a common sense approach *P.R. Jackson*

625 Index